ArticleArthritis and rheumatism2011
Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis.
Article in Arthritis and rheumatism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 69 citations in OpenAlex.
- In vitro anti-inflammatory potential and in vivo anti-arthritis activities of Ximenia caffra extract on antigen-induced arthritis in rats.Scientific reports · 2026Article
- Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?International journal of molecular sciences · 2025Review
- The Spleen Modulates the Balance of Natural and Pathological Autoantibodies in a Mouse Model of Autoimmune Arthritis.International journal of molecular sciences · 2024Article
- Splenectomy at early stage of autoimmune arthritis delayed inflammatory response and reduced joint deterioration in mice.Clinical and experimental immunology · 2024Article
- Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines.Frontiers in immunology · 2024Review
- Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review.Medicina (Kaunas, Lithuania) · 2023Review
- Splenectomy modulates the immune response but does not prevent joint inflammation in a mouse model of RA.Clinical and experimental immunology · 2022Article
- Immunomodulatory role of T helper cells in rheumatoid arthritis : a comprehensive research review.Bone & joint research · 2022Article
- Emerging proteoglycans and proteoglycan-targeted therapies in rheumatoid arthritis.American journal of physiology. Cell physiology · 2022Review
- Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models.Biomedicines · 2021Review
- Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis.Nature communications · 2021Article
- Article
- Review
- Ameliorated Autoimmune Arthritis and Impaired B Cell Receptor-Mediated CaInternational journal of molecular sciences · 2020Article
- Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase.Arthritis research & therapy · 2020Article
- DNA Methylation-Governed Gene Expression in Autoimmune Arthritis.International journal of molecular sciences · 2019Review
- PD-L1- and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease.JCI insight · 2019Article
- ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis.Cells · 2019Article
- Citrullinated Aggrecan Epitopes as Targets of Autoreactive CD4+ T Cells in Patients With Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2019Article
- Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review.Journal of clinical & cellular immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo develop a simplified and relatively inexpensive version of cartilage proteoglycan-induced arthritis (PGIA), an autoimmunity model of rheumatoid arthritis (RA), and to evaluate the extent to which this new model replicates the disease parameters of PGIA and RA.
methodsRecombinant human G1 domain of human cartilage PG containing "arthritogenic" T cell epitopes was generated in a mammalian expression system and used for immunization of BALB/c mice. The development and progression of arthritis in recombinant human PG G1-immunized mice (designated recombinant human PG G1-induced arthritis [GIA]) was monitored, and disease parameters were compared with those in the parent PGIA model.
resultsGIA strongly resembled PGIA, although the clinical symptoms and immune responses in mice with GIA were more uniform than in those with PGIA. Mice with GIA showed evidence of stronger Th1 and Th17 polarization than those with PGIA, and anti-mouse PG autoantibodies were produced in different isotype ratios in the 2 models. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected in both models; however, serum levels of IgG-RF and anti-CCP antibodies were different in GIA and PGIA, and both parameters correlated better with disease severity in GIA than in PGIA.
conclusionGIA is a novel model of seropositive RA that exhibits all of the characteristics of PGIA. Although the clinical phenotypes are similar, GIA and PGIA are characterized by different autoantibody profiles, and the 2 models may represent 2 subtypes of seropositive RA, in which more than 1 type of autoantibody can be used to monitor disease severity and response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.